Psychiatric symptoms in idiopathic rapid-eye-movement sleep behaviour disorder by Tuineag, Maria
i 
 
 
 
Université de Montréal 
 
 
Psychiatric symptoms in idiopathic rapid-eye-movement sleep behaviour 
disorder 
 
by 
 
Maria Ţuineag 
 
Department of Psychiatry 
Faculty of Medicine 
 
Master’s Thesis Presented to the Faculty of Superior Studies 
In Partial Fulfillment of the Requirements for the Degree 
Master of Science (M.Sc.) 
in Biomedical Sciences 
 
 
 
May 2012 
© Maria Ţuineag 
ii 
 
 
 
Université de Montréal 
Faculty of Superior Studies 
 
 
This thesis, entitled 
Psychiatric symptoms in idiopathic rapid-eye-movement sleep behaviour 
disorder 
 
 Presented by 
  Maria Ţuineag 
 
 
Was evaluated by a jury composed by 
Dr. Marie Dumont, PhD 
President 
 
Dr. Jean-François Gagnon, PhD 
Research director 
 
Dr. Jacques Montplaisir, MD, PhD 
Research co-director 
 
Dr. Roger Godbout, PhD 
Jury member 
 
iii 
 
 
 
Sommaire 
Le trouble comportemental en sommeil paradoxal (TCSP) idiopathique est caractérisé 
par une activité motrice indésirable et souvent violente au cours du sommeil paradoxal. 
Le TCSP idiopathique est considéré comme un facteur de risque de certaines maladies 
neurodégénératives, particulièrement la maladie de Parkinson (MP) et la démence à 
corps de Lewy (DCL). La dépression et les troubles anxieux sont fréquents dans la MP 
et la DCL. L’objectif de cette étude est d’évaluer la sévérité des symptômes dépressifs 
et anxieux dans le TCSP idiopathique. 
Cinquante-cinq patients avec un TCSP idiopathique sans démence ni maladie 
neurologique et 63 sujets contrôles ont complété la seconde édition du Beck Depression 
Inventory (BDI-II) et le Beck Anxiety Inventory (BAI). Nous avons aussi utilisé le BDI 
for Primary Care (BDI-PC) afin de minimiser la contribution des facteurs confondant 
dans les symptômes dépressifs.  
Les patients avec un TCSP idiopathique ont obtenu des scores plus élevés que les sujets 
contrôles au BDI-II (9.63 ± 6.61 vs. 4.32 ± 4.58; P < 0.001), au BDI-PC (2.20 ± 2.29 
vs. 0.98 ± 1.53; P = 0.001) et au BAI  (8.37 ± 7.30 vs. 3.92 ± 5.26; P < 0.001). Nous 
avons également trouvé une proportion plus élevée des sujets ayant des symptômes 
dépressifs (4/63 ou 6% vs. 12/55 ou 22%; P = 0.03) ou anxieux (9/50 or 18% vs. 21/43 
ou 49%; P = 0.003) cliniquement significatifs. La proportion des sujets ayant des 
symptômes dépressifs cliniquement significatifs ne change pas en utilisant le BDI-PC 
(11/55 or 20%) 
Les symptômes dépressifs et anxieux sont fréquents dans le TCSP idiopathique. 
L’examen de routine des patients avec un TCSP idiopathique devrait inclure un 
dépistage systématique des symptômes dépressifs et anxieux afin de les prévenir ou les 
traiter.  
 
Mots clé: trouble comportemental en sommeil paradoxal, dépression, anxiété, maladie 
de Parkinson, démence à corps de Lewy 
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Summary 
Idiopathic rapid-eye-movement sleep behaviour (iRBD) disorder can be a premotor 
feature of Parkinson’s disease (PD) or dementia with Lewy bodies (DLB). Depressive 
and anxiety symptoms are frequent nonmotor features in PD or DLB. We assessed the 
frequency and severity of depressive and anxiety symptoms in patients with iRBD 
compared to healthy control subjects. Fifty-five iRBD patients and 63 age and sex-
matched healthy subjects were studied. Participants completed the Beck Depression 
Inventory – Second Edition (BDI-II) and Beck Anxiety Inventory (BAI). We assessed 
the depressive and anxiety symptoms and compared the proportion of participants with 
clinically significant depressive or anxiety symptoms. We also used the BDI for 
Primary Care (BDI-PC) to minimize confounding factors that could overestimate 
depressive symptoms. iRBD patients scored higher than controls on the BDI-II (9.63 ± 
6.61 vs. 4.32 ± 4.58; P < 0.001)), BDI-PC (2.20 ± 2.29 vs. 0.98 ± 1.53; P = 0.001) and 
BAI  (8.37 ± 7.30 vs. 3.92 ± 5.26; P < 0.001). Compared to controls, we found a higher 
proportion of patients with iRBD with either clinically significant depressive (4/63 or 
6% vs. 12/55 or 22% P = 0.03) or anxiety symptoms (9/50 or 18% vs. 21/43 or 49%; P 
= 0.003). The proportion of iRBD patients with clinically significant depressive 
symptoms remains unchanged using the BDI-PC (11/55 or 20%). Depressive and 
anxiety symptoms are frequent features in iRBD. Routine examination of patients with 
iRBD disorder should include an assessment of depressive and anxiety symptoms in 
order to prevent or treat them.  
 
Key words: REM sleep behaviour disorder, depression, anxiety, Parkinson’s disease, 
dementia with Lewy bodies 
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1. GENERAL INTRODUCTION 
Throughout the history of medicine, defining sleep has been a daunting challenge due to 
its complex cyclical generation pattern, its importance for individual functioning, and 
its involvement in pathology. According to a behavioural definition, sleep is a 
reversible behavioural state of perceptual disengagement from and unresponsiveness to 
the environment (Principles and Practice of Sleep Medicine, Meir H. Kryger, Thomas 
Roth and William C. Dement, 5th Edition, 2011). From a neurobiological standpoint, 
human sleep is defined in terms of a series of physiological changes revealed by a sleep 
recording procedure called polysomnography (PSG). PSG is a multiparametric test that 
records electroencephalographical activity (EEG), ocular movements using an 
electrooculogram (EOG), and muscle tone using an electromyogram (EMG). 
 
Based on these three parameters (EEG, EOG, and EMG), three distinct states of 
consciousness can be identified: wakefulness, non-rapid-eye-movement (NREM) sleep, 
and rapid-eye-movement (REM) sleep. NREM sleep is further subdivided into four 
stages: 1, 2, 3, and 4. Stages 3 and 4 are collectively referred to as slow-wave sleep 
(SWS) (Rechtschaffen and Kales, 1968). 
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1.1 Wakefulness 
In basal conditions (supine position, eyes closed, in a dark, quiet room) EEG activity 
during wakefulness is predominated by alpha-rhythm, which is more prominent in 
occipital leads. Alpha waves have a frequency range of 8 to 13 Hz and average 
amplitude of about 50 µV. This rhythm reflects a relaxation state and is abruptly 
replaced by the beta rhythm—a more rapid and desynchronized activity—when subjects 
are visually or cognitively stimulated.  
 
1.2 Non-rapid-eye-movement (NREM) sleep 
Stage 1 sleep appears in the transition from wakefulness to other sleep stages, or 
following partial arousals during sleep. Alpha activity decreases or disappears and is 
replaced by a recording characterized mostly by low-amplitude theta waves (4–8 Hz). 
At this time, EMG activity decreases and EOG shows slow rolling eye movements. As 
sleep deepens, stage 2 occurs, accounting for approximately 50% of the total sleep time. 
The hallmark of stage 2 is the presence of sleep spindles and K-complexes. K-
complexes are relatively high amplitude biphasic waves with an initial negative 
component and a total duration of at least 0.5 seconds. They are believed to occur 
spontaneously, but can be associated with sensory stimuli and often precede arousal. 
Spindles are commonly known as a group of rhythmic waves characterized by 
progressively increasing, then gradually decreasing, amplitude. They may occur at 
different frequencies of 10 to 16 Hz, but Rechtschaffen and Kales specifically define 
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spindles associated with the onset of stage 2 as heaving a frequency of 12 to 14 Hz and 
duration of 0.5 to 1.5 seconds (Harris, 2005).  
 
SWS (stages 3 and 4) is characterized by high-amplitude (> 75 µV) delta waves (0.5–4 
Hz). In 1968, Rechtschaffen and Kales set the criteria for stages 3 and 4 SWS. The 
appearance of high-amplitude delta activity for more than 20% of a 30-second epoch is 
scored as stage 3 sleep, and >50% as stage 4. Although K-complexes and spindles may 
appear during SWS, they may be masked by high-amplitude delta activity. 
  
1.3 Rapid-eye-movement (REM) sleep 
REM sleep accounts for about 25% of sleep time. As the sleep cycles unfold during the 
night, the tendency shifts from an abundance of SWS during the first part of the night to 
a preponderance of REM sleep during the second part. REM sleep may be divided into 
a phasic and tonic phase. The tonic phase is characterized by an EEG desynchronization 
and striated muscle atonia (except for the diaphragm). In addition to EEG 
desynchronization, the phasic phase features rapid eye movements and a series of other 
phenomena such as contractions of the muscles of the medium ear, autonomic 
fluctuations (irregular pulse and breathing), erections, vasodilatation of the pelvic 
organs, and clonic twitches of the face and extremities. The rapid eye movements are 
saccadic, predominantly horizontal and occur in bursts or alone. On the EEG, saw-tooth 
waves (in the theta range, 4-7 Hz) may appear in conjunction with eye movements.  
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Waking EEG is also characterized by desynchronization, a diffuse pattern of relatively 
low-amplitude, mixed-frequency activity that includes higher frequency beta activity. 
Comparatively to REM sleep, EOG and EMG activity during wakefulness is very 
variable and is strictly related to the activity the subject is engaged in. When the subject 
is cognitively active, eye movements are rapid and variable in direction, with 
intermixed blinking. On eye closure, eye movements may be absent with occasional 
blinks in response to stimuli. EMG also varies widely in wakefulness, ranging from 
gross body movements that may obscure EEG and EOG activity to a diminished 
activity with constant tonus during relaxed wakefulness. 
REM appears to be a state in which the awakened brain is trapped in a paralyzed body, 
hence the term “paradoxical sleep,” where an activated brain operates in a seemingly 
unresponsive organism. REM sleep is associated with vivid dreaming, although more 
and more reports indicate mental activity in NREM sleep as well.  
 
1.3.1 The relation between dreaming and sleep stages 
The initial perspective on the relationship between dreams and sleep stage was referred 
to by many as the “REM sleep = dreaming” perspective from which dreaming was 
viewed as a characteristic exclusive to REM sleep. Mentation reported from NREM 
sleep was attributed to confounding factors, for example recall of mentation from 
previous REM episodes or subjects’ waking confabulations. However, subsequent 
studies cast doubt on this perspective (Foulkes, 1962) primarily by demonstrating 
elevated levels of mentation recalled from NREM sleep stages. Although the “REM 
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sleep = dreaming” remains a widespread theory, a debate over whether the quality of 
NREM and REM sleep mentation reports differ, largely overshadowed it. Initially, 
qualitative differences in REM and NREM reports suggested that a different form of 
mentation occurs in NREM sleep. From these developments, two relatively distinct 
points of view concerning REM/NREM mentation emerged and continue to influence 
the field. These points of view differ as to whether they consider NREM sleep 
mentation to originate from imagery processes that are fundamentally the same as or 
different from those that produce REM sleep mentation. Nielsen (2000) refers to these 
as the 1-generator and 2-generator models. Although dreams can be produced in SWS 
(Foulkes, 1962), dreams during REM sleep are the most typical with a rich and varied 
content involving emotion and motor behavior. Animal research shows that when the 
regions responsible for the muscle atonia in RBD are injured, fight-or-flight behaviors 
appear while other signs of REM sleep (EEG, visual system) are still present 
(Hendricks et al, 1982). Mentation differences originate primarily from differences in 
memory activation. When such activation is high and diffuse, during most REM but 
some NREM sleep, then organization is more intensely stimulated and conscious 
interpretation more probable and coherent, giving rise to the more vivid and memorable 
dreams associated with REM sleep. When memory activation is low and less diffuse, 
during most NREM but some REM sleep, then organization is less intensely stimulated 
and conscious interpretation less probable and coherent. It is thus the diffuseness or 
availability of diverse memory elements and not sleep stage physiology that determines 
the occurrence and form of sleep mentation (Nielsen, 2000). 
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1.3.2 The mechanism of REM sleep 
Luppi et al. (2010) proposed in their rat model study an updated theory of REM sleep 
onset and maintenance. According to Luppi, REM sleep is induced by the activation of 
glutamatergic neurons found in the sublateral tegmental dorsal nucleus (SLD) in the 
caudal pons. These findings support earlier studies according to which neurons in SLD 
that trigger REM sleep are indeed glutamatergic (Lu et al., 2006; Clement et al., 2009). 
These REM-on neurons (neurons that fire during REM sleep) are actively inhibited 
during wakefulness and SWS by GABA-ergic REM-off neurons (neurons that cease 
fire during REM sleep) localized in the ventral part of a neuronal complex that 
comprises the vlPAG (ventrolateral periaqueductal grey) and dDpMe (dorsal deep 
mesencephalic reticular nucleus). These REM-off neurons are activated during 
wakefulness by hypocretin and aminergic neurons projecting from the hypothalamus. 
Two other REM sleep generators have been localized in the hypothalamus 
(melanin/GABA-ergic neurons), in the dorsal part of the vlPAG – dDpMe complex and 
in the paragigantocellular reticular nucleus (DPGi) These REM-on neurons have an 
intrinsic “clock-like” mechanism that allow periodic initiation of the REM sleep. They 
also inhibit the wakefulness-promoting hypocretin, aminergic, and GABA-ergic 
neurons, thus creating a reciprocal inhibition-activation network. 
Escaping from the inhibition of the waking-promoting neurons (REM-off), the REM-on 
neurons localized in the ventral part of the SLD project in an ascending way inducing 
cortical activation via intralaminar thalamic relay neurons. This activation occurs in 
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collaboration with wakefulness/REM-on cholinergic neurons and glutamatergic neurons 
from the laterodorsal tegmental nucleus (Ltd), the pedunculopontine (PPN), 
mesencephalic, and pontine reticular nuclei and the basal forebrain. At the same time, 
glutamatergic REM-on neurons in the caudal part of the SLD induce muscle atonia and 
sensory inhibition projecting to anterior spinal cord alpha motor neurons via excitatory 
projections to the glycinergic nuclei located in the medulla a (ventral – Giv and alpha - 
Gia gigantocellular nuclei). This network also blocks impulses from the motor cortex 
which are responsible with movement associated to the dream content, so motor control 
in REM sleep is acquired by means of two systems: tonus abolition through a 
descending way (SLD – GiV/GiA – motors neurons in the spinal cord) and inhibition of 
dream enactment movements from the motor cortex.  
A major discovery regarding REM inhibition in rats was that serotonergic neurons from 
the raphe nuclei and noradrenergic neurons from the locus coeruleus cease firing 
specifically during REM sleep, i.e., they show a REM-off firing activity, reciprocal to 
that of REM-on neurons. Luppi proposes that rather than inhibiting directly SLD REM-
on neurons, noradrenaline and serotonin might inhibit REM by means of a tonic 
excitation of the dDPMe and vlPAG REM-off GABAergic neurons. Partly supporting 
this hypothesis, noradrenaline but not serotonin application in the dDPMe was shown to 
increase wakefulness and decrease SWS and REM sleep (Luppi et al, 2010). 
Similar to the studies in rats, the main nucleus responsible for triggering REM sleep 
(REM-on cells) has been identified in cats as the noradrenergic complex locus 
coeruleus/ subcoeruleus nucleus (Siegel, 2006), the equivalent of the SLD in rats. The 
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lack of coherence regarding the neurotransmitter involved in the REM-trigger centers 
between studies performed on rat and cat is regarded as an inter-species variability 
(Luppi et al, 2011). Other regions identified from lesion studies in cats are the 
medullary magnocellular reticular formation (MCRF)—which is the final common 
pathway of spinal motor neuron inhibition, the PPN (pedunculopontine nucleus) and the 
Ldt.  
The dopaminergic substantia nigra (SN) has been proposed as a component of this REM 
sleep system due to its apparent role in lesion studies, but there is a paucity of direct 
evidence to implicate this nucleus. (Boeve et al, 2007). 
 
1.4 Sleep disorders 
The International Classification of Sleep Disorders, Second Edition (ICSD-II, 2005) 
categorizes sleep disorders into four categories: dysomnias, parasomnias, sleep 
disorders associated with mental, neurologic, or other medical disorders, and proposed 
sleep disorders (disorders for which there is insufficient information available to 
confirm the unequivocal existence of the disorder, e.g., subwakefulness syndrome).  
 
According to Principles and Practice of Sleep Medicine, 5th Edition (2011), 
parasomnias are defined as “unpleasant or undesirable behavioural or experiential 
phenomena that occur predominantly or exclusively during the sleep period.” Primary 
parasomnias (i.e., sleep disorders per se) can be categorized by the sleep state in which 
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they occur, such as NREM arousal parasomnias, REM parasomnias, and miscellaneous 
parasomnias (irrespective of the sleep state). 
NREM arousal parasomnias are characterized by a state of dissociation in which the 
brain is partially awake and partially in NREM sleep. The brain is awake enough for 
performing very complex motor and verbal tasks, but is asleep enough not to have 
conscious awareness of or responsibility for the actions. This category of parasomnias 
include somnambulism (sleepwalking), confusional arousals and sleep terrors. 
Sleepwalking episodes are partial arousals typically from slow wave sleep during the 
first half of the sleep period. These events can be minor or elaborate behaviours such as 
dressing, unlocking locks and even driving. The patients do not exhibit significant 
autonomic features (tachycardia, sweating, etc) or expression of fear. These elements 
help differentiate somnambulism from sleep terrors which are a more intense form of 
arousal disorders with a predominance of autonomic expression. The patient arises 
suddenly with a piercing scream or cry, autonomic output and behavioural 
manifestation of intense fear. The onset of the episode is abrupt and the patient displays 
tachycardia, flushing, diaphoresis and mydriasis. They typically appear in the first third 
of the night and patients have no memory of the event. As with somnambulism, patients 
have a normal neurological examination during wakefulness. Both sleepwalking and 
night terrors are childhood-onset disorders and they usually are self-limited, symptoms 
disappearing by adulthood. Confusional arousals can occur from any arousal from slow 
wave sleep. They consist of disorientation, slow speech and mentation or inappropriate 
behaviour. Unlike somnambulism and sleep terrors, patients with confusional arousal 
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have partial memory impairment of the event (Principles and Practice of Sleep 
Medicine, 5
th
 Edition (Chapter 60 - Classification of sleep disorders, Michael J. 
Thorpy).  
 
REM parasomnias usually reflect a dissociated sleep state in which not all the elements 
leading to the initiation and maintenance of REM sleep appear to function.  This is very 
well illustrated by REM sleep behaviour disorder (RBD), a sleep parasomnia in which 
normal muscle atonia is missing. Other REM sleep parasomnias include nightmares, 
REM-related painful penile erections and REM-related sinus arrest.  
 
2. REM SLEEP BEHAVIOUR DISORDER (RBD) 
2.1 Definition and clinical features  
RBD was first described as a distinct clinical condition by Schenck and Mahowald 
(Schenck et al., 1986). According to the ICSD-II, RBD is characterized by the 
intermittent loss of REM sleep EMG atonia and the appearance of elaborate motor 
activity associated with dream mentation (dream enactment). In patients with RBD, 
both the tonic and phasic component of REM sleep are altered. Partial or complete loss 
of tonic chin EMG atonia (REM sleep without atonia) and excessive chin and limb 
phasic EMG activity are characteristic features in patients with RBD (Schenck et al., 
1993). 
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The three core clinical aspects of RBD are abnormal vocalization, abnormal motor 
behaviour, and altered dream mentation. Although vocalization is often encountered in 
the general population, vocalization in RBD patients tends to be loud, suggesting 
unpleasant dreams. The abnormal vocalization ranges from shouting to screaming and 
swearing (Boeve et al., 2010). Excessive muscular activity during REM sleep often 
leads to undesirable motor behaviours such as kicking, punching, falling out of bed, or 
even running (Schenck et al., 2002). These abnormal behaviours may cause injuries to 
the patient or bed partner, ranging from ecchymoses to subdural hematoma (Olson et 
al., 2000). 
 
Most RBD patients report vivid nightmares, with a surprisingly consistent content 
involving insects, animals, or people chasing or attacking them, their relatives, or their 
friends. The patient is almost always the defender and not the attacker (Boeve, 2010). In 
addition, the aggressiveness displayed during dreaming is in flagrant contrast to the 
somewhat calm and mild-mannered temperament of the patient during wakefulness 
(Schenck et al., 2002; Olson et al., 2000, Fantini et al., 2005). Moreover, sexual dream 
content was not reported by RBD patients compared to the dream content of normal 
subjects (Fantini et al., 2005). RBD usually appears in the fifth decade of life, although 
symptoms can appear as early as adolescence. Based on a large series study with 4,972 
participants ranging in age from 15 to 100 years, RBD prevalence was estimated at 
0.5% in the general population (Ohayon et al., 1997). Traditionally, RBD is described 
as a strikingly male-predominant parasomnia, with 80% of patients being men (Wing et 
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al., 2008). This difference might have a hormonal basis, or alternatively, because 
women display milder symptoms, they would be less likely to seek medical help 
(Schenck et al., 1993).  
2.2 Diagnostic criteria, differential diagnosis, and treatment of RBD 
The ICSD-II lists four major criteria as the diagnosis of RBD:  
A. Presence of REM sleep without atonia: the EMG finding of excessive amounts of 
sustained or intermittent elevation of submental EMG tone or excessive phasic 
submental or (upper or lower) limb EMG twitching; 
B. At least one of the following is present: 
1. Sleep-related, injurious, potentially injurious or disruptive behaviour by history  
2. Abnormal REM sleep behaviour documented during PSG monitoring;  
C. Absence of EEG epileptiform activity during REM sleep unless RBD can be clearly 
distinguished from any concurrent REM sleep related seizure disorder;  
D. The symptoms are not better explained by another sleep disorder, medical or 
neurological disorder, mental disorder, medication or substance use disorder. 
 
REM sleep without atonia (RSWA) refers to the electrophysiological finding of loss of 
complete or partial EMG atonia during REM sleep. It is one of the features sought in 
PSG when evaluating a patient with suspected RBD. According to Montplaisir et al. 
(2010), the polysomnographic cut-offs for excessive muscular activity are tonic chin 
EMG density ≥30% of total REM sleep time, phasic chin EMG density ≥15% of total 
REM sleep time, and ≥24 leg movements per hour of REM sleep. Each 20-second 
13 
 
 
 
epoch on the PSG was scored as tonic or atonic depending if EMG activity was present 
for more or less than 50% of the epoch duration. Excessive EMG activity was defined 
by amplitude of chin EMG signal of at least twice that of the background or greater than 
10 µV. Phasic chin EMG density was scored from the submental EMG activity and 
represented the percentage of 2-seconds mini-epochs containing EMG events lasting 
0.1 to 10 seconds, with an amplitude exceeding four times the amplitude of background 
EMG activity (Montplaisir et al, 2010). 
The differential diagnosis of RBD includes the NREM parasomnias (somnambulism, 
night terrors, confusional arousals), nocturnal panic attacks, nocturnal seizures, 
nightmares, nocturnal wandering associated with dementia, and obstructive sleep apnea 
(OSA). The history usually allows differentiating these disorders from RBD. As stated 
above, both sleepwalking and night terrors are childhood-onset disorders and they 
usually are self-limited, symptoms disappearing by adulthood, whereas RBD has an 
onset typically around the age of 50. The RBD episodes usually occur in the second part 
of the night, which is prevalent in REM sleep, with non-stereotyped movements and 
violent verbalization, eyes closed and clear recollection of the dream upon awakening 
(Leu-Semenescu and Arnulf, 2010). Sleepwalking arises mainly in the first third of the 
night, when there is an abundance of slow wave sleep. However, when diagnostic 
clarification is necessary, particularly when the risk for injury is high, the behaviours 
occur at any time of the night or when symptoms suggestive of OSA are observed, PSG 
with simultaneous video monitoring should be used (Boeve et al., 2010). 
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To date, no double-blind, placebo-controlled clinical trials have assessed the efficacy of 
any treatment for RBD. The mainstay treatment for RBD remains clonazepam in doses 
ranging from 0.5 mg to 2 mg at bedtime (Gagnon et al., 2006). Clonazepam is a 
benzodiazepine that completely inhibits excessive motor behaviour during RBD 
episodes in approximately 80% of patients: another 10% of patients have partial benefit 
(Schenck et al., 1993) and 10% don’t benefit at all from the drug. Clonazepam slightly 
decreases phasic activity in the EMG, but does not restore the normal muscular atonia 
in patients under treatment (Lapierre and Montplaisir, 1992) (Sforza,1997). The 
mechanism of action of clonazepam in RBD is unknown, but the fact that it results in 
striking clinical improvement without PSG changes on the tonic EMG activity raises 
the possibility that it preferentially acts on locomotor systems (namely the inhibition of 
the motor cortex projection) rather than on those that control REM muscle atonia 
(Watanabe and Sugita, 1998). When clonazepam is ineffective, melatonin (3–12 mg) 
has been shown to have some effect used alone or in conjunction with clonazepam 
(Kunz, et al., 1999; Boeve et al., 2003). Unlike clonazepam, melatonin restores muscle 
atonia in RBD patients (Iranzo et al., 2009).  
 
There have been numerous reports of RBD onset associated with some medications. 
The most often cited are selective serotonin reuptake inhibitors such as fluoxetine, 
paroxetine, sertraline, and citalopram (Shenck et al 1992; Winkelman et al, 2004); the 
tetracyclic antidepressive mirtazapine (Onofrj et al., 2003; Nash et al., 2003), and the 
MAO inhibitors phenelzine and selegiline (Akindele et al., 1970) (Gagnon et al., 2006). 
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RBD symptoms have also been well documented after alcohol withdrawal. However, 
idiopathic RBD can be differentiated from drug-induced RBD by thorough 
documentation of the onset of symptoms in relation to the time of drug use or by 
removing the offending drug, moment that usually corresponds to a the ceasing of RBD 
symptoms. 
Sleep architecture is preserved in idiopathic RBD, with comparable values to healthy 
age-matched subjects for total sleep time, sleep efficiency, and REM sleep percent and 
efficiency (Montplaisir et al, 2010; Fantini et al, 2003). Some quantitative EEG studies 
found a slowing of the EEG during REM sleep in idiopathic RBD (Fantini et al., 2003; 
Iranzo et al., 2010). However, a recent study performed in our laboratory found no 
slow-wave anomalies in idiopathic RBD compared to control subjects (Latreille et al, 
2011). These results suggest a specific neuropathologic damage to centers controlling 
REM sleep preferentially, sparing other sleep components. 
 
2.3 Pathophysiology of RBD  
The pathophysiology of RBD has been hypothesized based on studies in animals, 
including cats and rats, from pharmacological manipulations and imaging studies of 
brainstem lesions in humans. 
As explained above in the rat model proposed by Luppi (Luppi et al., 2011), the SLD 
nucleus involved in the mechanism of  REM sleep has two distinct subpopulations of 
neurons: an ascending group that induces cortical activation and a descending group 
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that is responsible for muscle atonia during REM sleep. Thus, the absence of atonia 
during an RBD episode could be due to the degeneration of either the descending 
subpopulation of glutamatergic neurons in the SLD or the nuclei in the lower part of the 
network (i.e., the GABA/glycinergic GiA and GiV)  that control muscle tone via the 
alpha motoneurons in the anterior horns of the bone marrow. If this latter theory is true, 
this would explain why the neurons in the SLD degenerate preferentially to abolish 
atonia only but preserve the other components of REM sleep such as dreaming which 
supposedly is induced by the ascending projection of the ventral part of the SLD to the 
cortex.. Although it remains to be confirmed whether these two SLD neuron 
subpopulations are present in rats, they have been identified in cats (Lai and Siegel, 
1997).  
Although RBD has been strongly associated to PD, several studies indicate that it is 
unlikely its pathophysiology is due mainly to the dysfunction of the dopaminergic 
nigrostriatal system (Kim et al, 2010) Arguments supporting this assertion are the fact 
that about half of RBD patients do not develop PD, that the treatment with 
dopaminergic agents usually does not improve RBD and that medication such as 
selective serotonin-reuptake inhibitors can exacerbate or even induce RBD. However, 
an imagery study by Iranzo et al (2010) found changes in subtantia nigra of iRBD 
patients similar to those in patients with Parkinson’s disease, which might suggest that 
at least a part of the iRBD subjects have a substantia nigra dopaminergic related 
dysfunction. Lesions in the subcoeruleus/coeruleus complex (and/or possibly in the 
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PPN as well) cause REM sleep without atonia, and lesion size determines the 
complexity of motor behaviour (Hendricks et al., 1982). 
 
Only a few cases of RBD associated with brainstem lesions have been reported in 
humans, using single-case imaging studies. Reports range from patients with new-onset 
RBD after a presumably ischemic lesion in the left upper pons (Kimura et al., 2000) to 
multiple sclerosis lesions in pontine white matter (Plazi and Montagna, 2002) and 
tumours located in the brainstem (Zambelis et al., 2002). Moreover, data from two RBD 
patients who underwent post-mortem neuropathological analysis showed brainstem-
predominant Lewy bodies disease with degeneration of the substantia nigra and 
coeruleus/subcoeruleus complex (Uchiyama et al., 1995; Boeve et al., 2007). In 
conclusion, although the neuronal structures involved in RBD have not been 
definitively established, it is widely acknowledged that they are located in the 
brainstem. 
 
2.4 Idiopathic versus secondary RBD: association with neurodegenerative disorders 
RBD can be a self-standing entity (termed idiopathic) (iRBD), without any apparent 
concomitant neurological disease. It can also be found concomitantly with 
neurodegenerative diseases, especially synucleinopathies such as Parkinson’s disease 
(PD), dementia with Lewy bodies (DLB), and multisystem atrophy (MSA), and it is 
then termed secondary RBD (Gagnon et al., 2006). Moreover, iRBD has been 
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recognized as an early sign of synucleinopathies, being part of a cluster of premotor 
signs of these diseases. Premotor signs are considered to be the result of the earliest 
pathological changes. It is now widely accepted (Braak et al, 2003) that the pathology 
of PD begins in a variety of central and peripheral system regions (notably the nucleus 
of vagus nerve in the medulla oblongata, or even in the peripheral autonomic system) 
before the involvement of the substantia nigra and the appearance of the motor 
symptoms. Features arising from this involvement have been described with terms such 
as “preclinical”, “prodromal or “premotor” (Lang, 2010). Lately, several 
synucleinopathy markers deemed “premotor”, have been identified in iRBD patients, 
such as cognitive and olfactory impairment, subtle motor abnormalities, cardiac 
autonomic dysregulation, and other autonomic manifestations such as constipation, 
erectile dysfunction, and urinary retention (Gagnon et al., 2009; Postuma et al., 2009; 
Lanfranchi, 2007; Postuma and Montplaisir, 2006). These findings indicate that RBD is 
an early manifestation of a neurodegenerative process, thus challenging the notion of 
idiopathic RBD. 
Several series of iRBD patients have been followed prospectively, showing that a 
majority have converted to some type of neurodegenerative disease, particularly 
synucleinopathies such as PD, DLB, and MSA. In their follow-up study, Schenck et al. 
showed that 38% of iRBD patients developed a parkinsonian syndrome 3.7 years after 
diagnosis and after a mean interval of 12.5 years from the onset of symptoms (Schenck 
et al., 1996). Iranzo and colleagues reported on a series of 44 patients with iRBD with 
at least 2 years of clinical follow-up, of whom 45% developed a neurological disorder 
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after a mean of 11.5 years from the reported onset of RBD. A majority of the converted 
patients (9/20 or 45%) developed PD (Iranzo et al., 2006). Another major prospective 
study (Postuma et al., 2009) performed on 93 iRBD patients found the estimated 5-year 
risk for neurodegenerative disease at 17.7%, the 10-year risk at 40.6%, and the 12-year 
risk at 52.4%. Twenty-six patients developed a neurodegenerative disorder: PD in 14, 
DLB in 7, probable Alzheimer’s disease (AD) in 4 and MSA in 1. 
 
Although it is difficult to explain why not all iRBD patients convert to some 
neurodegenerative disease, and why they seem to remain in a ‘frozen’ 
neuropathological state, a step has been made towards identifying a marker for patients 
who will eventually convert. Postuma et al. (2010) found that in patients with iRBD 
who were initially free of neurodegenerative disease, the severity of REM atonia loss on 
baseline PSG (Postuma et al., 2010) as well as olfaction and colour vision impairment 
(Postuma et al., 2011) predict the development of synucleinopathies.  
 
3. PSYCHIATRIC DISORDERS IN RBD  
At least two other potential pre-motor symptoms concomitant with iRBD have been 
suggested: depression and anxiety. Psychiatric symptoms such as depression and 
anxiety are frequent non-motor features of PD, DLB, and MSA, and they can 
considerably complicate the course of the disease (Aarsland et al., 2007; Benrud-Larson 
et al., 2005; Dodel et al., 2008). Although it has been suggested that depression and 
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anxiety are associated with difficulty in accepting the diagnosis of an incurable 
evolving disease, PD patients tend to have more severe depressive symptoms than 
patients with other chronically disabling diseases (Ehmann et al., 1990). Moreover, 
depression and anxiety often develop before the onset of parkinsonism in PD and DLB 
(Weisskopf et al., 2003; Remy et al., 2005). Depression and anxiety can be difficult to 
assess in patients with PD due to overlapping symptoms and the difficulty of assessing 
depression in cognitively impaired patients. A variety of scales are available to assess 
these two psychiatric disorders in PD patients. The Beck Depression Inventory (BDI) is 
one of the most commonly used self-rated instruments for major depression in clinical 
practice (Watkins et al., 1995). The BDI is suitable for screening if an appropriate 
cutoff is used. It is also suitable for assessing the severity of depressive symptoms and 
for monitoring changes during treatment. In addition, it can be used in 
phenomenological studies of depression in PD (Schrag et al., 2007). The Beck Anxiety 
Inventory (BAI) assesses anxiety symptoms. It consists of a questionnaire containing 21 
items to measure the severity of somatic, affective, and cognitive symptoms associated 
with panic attacks and generalized anxiety. The BAI has not been validated in PD. 
However, it meets the criteria for the suggested scale to screen for symptoms of panic 
attacks in PD patients. It is probably less suitable to screen for other anxiety disorders. 
It also meets the criteria for the recommended scale for determining the epidemiology 
and markers of anxiety symptoms, and for monitoring changes in symptom severity 
after treatment (Leentjens et al., 2008). 
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Only a small body of literature addresses psychiatric disorders in iRBD. In Schenck’s 
initial cohort, a psychiatric disorder and/or its treatment was causally associated with 
RBD onset in 9.4% of patients, but seven of nine cases had a definite organic origin: 
cessation of ethanol, amphetamine use, cocaine abuse, fluoxetine treatment of 
obsessive-compulsive disorder, and rapid imipramine withdrawal (Schenk et al., 2002). 
Wing et al. (2008) reported a lifetime prevalence of 33% (27/82) of psychiatric 
disorders in RBD, with a predominance of depression diagnosis (22%, 18/82) (Wing et 
al., 2008). Olson (Olson et al, 2000) reported a similar prevalence (25.8%). In their 
cohort of 93 RBD patients, Olson et al. (2000) found that psychiatric disorders included 
affective disorders (10), substance abuse (9), and personality disorders (3).  
 
Only one study to date has specifically addressed the issue of psychiatric disorders in 
iRBD. Teman et al., 2009 found that both early-onset and late-onset iRBD patients (age 
cut-off at 50 years) had significantly more past and present psychiatric diagnoses, 
mainly affective or anxiety disorders, than non-RBD controls (Teman et al., 2009). 
However, no studies have used validated scales to assess depressive or anxiety 
symptoms in iRBD. 
 
4. STUDY OBJECTIVES AND HYPOTHESIS 
STUDY OBJECTIVES 
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1. To assess the severity of depressive symptoms in patients with iRBD compared 
to healthy controls. 
2. To assess the severity of anxiety symptoms in patients with iRBD compared to 
healthy controls. 
3. To determine the proportion of individuals in each group with clinically 
significant depressive symptoms. 
4. To determine the proportion of individuals in each group with clinically 
significant anxiety symptoms. 
 
 
SCIENTIFIC HYPOTHESES 
1. Patients suffering from iRBD will have more severe depressive symptoms than 
sex- and age-matched healthy controls. 
2. Patients suffering from iRBD will have more severe anxiety symptoms than sex- 
and age-matched healthy controls. 
3. The proportion of individuals with significant clinical depressive symptoms will 
be higher in the iRBD group than in the control group. 
4. The proportion of individuals with significant clinical anxiety symptoms will be 
higher in the iRBD group than in the control group. 
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ABSTRACT 
Objectives: To assess the frequency and severity of depressive and anxiety symptoms in 
idiopathic REM sleep behavior disorder (iRBD), a risk factor for Parkinson’s disease (PD) or 
dementia with Lewy bodies (DLB).  
Design: Cross sectional case-control study. 
Setting: University hospital-based sleep research clinic. 
Participants: Fifty-five iRBD patients and 63 age and sex-matched healthy subjects.  
Measurements: Participants completed the Beck Depression Inventory – Second Edition 
(BDI-II) and Beck Anxiety Inventory (BAI). We assessed the depressive and anxiety 
symptoms and compared the proportion of participants with clinically significant depressive 
or anxiety symptoms. We also used the BDI for Primary Care (BDI-PC) to minimize 
confounding factors that could overestimate depressive symptoms.  
Results: iRBD patients scored higher than controls on the BDI-II (9.63 ± 6.61 vs. 4.32 ± 4.58; 
P < 0.001), BDI-PC (2.20 ± 2.29 vs. 0.98 ± 1.53; P = 0.001) and BAI  (8.37 ± 7.30 vs. 3.92 ± 
5.26; P < 0.001). Compared to controls, we found a higher proportion of iRBD patients with 
past psychiatric diagnoses (6/63 or 9.5% vs. 17/55 or 31%; P =  0.007), clinically significant 
depressive (4/63 or 6% vs. 12/55 or 22% P = 0.03) or anxiety symptoms (9/50 or 18% vs. 
21/43 or 49%; P = 0.003). Proportion of iRBD patients with clinically significant depressive 
symptoms remains unchanged using the BDI-PC (11/55 or 20%). 
Conclusions: Depressive and anxiety symptoms are frequent features in iRBD. Routine 
examination of patients with iRBD should include an assessment of depressive and anxiety 
symptoms in order to prevent or treat them. 
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INTRODUCTION 
Idiopathic REM sleep behavior disorder (iRBD) is a parasomnia characterized by excessive 
muscular activity during REM sleep. This often leads to undesirable verbal or motor 
behaviors which may cause injuries to the patient or bed partner (1-3). RBD prevalence has 
been estimated at 0.5% in the general population (4), predominantly affecting older males (5). 
Clonazepam is the first line of treatment for RBD (6). 
 
iRBD is an early harbinger for the development of some neurodegenerative diseases, 
especially synucleinopathies such as Parkinson’s disease (PD) or dementia with Lewy bodies 
(DLB). Studies have reported a risk of 40% or more of developing a synucleinopathy 10 years 
after an iRBD diagnosis (7-9). Sleep architecture remains well preserved in iRBD (10). 
However, many markers of PD or DLB have been reported in iRBD, including cognitive, 
olfactory, motor, and autonomic abnormalities (11,12). 
  
Although psychiatric symptoms such as depression and anxiety are frequents in PD and DLB 
(13-15), there is only a small body of literature that addresses depression and anxiety in 
iRBD. The past psychiatric diagnoses in iRBD has been estimated from 26 to 33% (2,5). 
Moreover, one study found that both early-onset and late-onset iRBD patients had 
significantly more past and present psychiatric diagnoses than non-RBD controls (16). 
However, no study to date has assessed depressive or anxiety symptoms in iRBD using 
validated scales. 
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The objectives of the present study are: 1) to assess the severity of depressive and anxiety 
symptoms in iRBD compared to healthy controls and to identify risk factors; 2) to determine 
the proportion of subjects with clinically significant depressive or anxiety symptoms; 3) to 
determine the proportion of iRBD patients with past psychiatric diagnoses. 
 
METHODS 
Participants 
All subjects gave their written informed consent prior to the experiment, and the study was 
approved by the Ethics Committee of Sacré-Coeur Hospital, Montreal. One hundred and 
thirty-four subjects, including 70 patients with iRBD and 64 healthy control subjects 
participated to this study. iRBD patients were recruited during their initial polysomnography 
(PSG) recording for RBD (N=30) or during their annual follow-up without PSG (N=40). All 
iRBD patients were referred to the sleep clinic by their general practitioner for a complaint of 
violent behavior during sleep. Control subjects were recruited in the community, via 
newspaper or word-of-mouth, to participate in a project of sleep and aging. All participants 
resided in the province of Quebec, Canada and completed at least a primary degree of 
education (none was illiterate). Inclusion criteria were the presence of video-PSG-confirmed 
RBD for patients with iRBD and the absence of RBD confirmed by one night video-PSG for 
control subjects (10). Participants were excluded for the following criteria: aged over 90 years 
old, dementia according to the DSM-IV criteria and a neuropsychological evaluation when 
available (17), parkinsonism, narcolepsy, drug-induced RBD or epilepsy. All iRBD patients 
underwent magnetic resonance imaging to exclude brain tumor and stroke. A comprehensive 
neurological evaluation was performed by a movement disorders specialist to exclude 
parkinsonism, according to UK Brain Bank criteria (18). RBD diagnosis was confirmed by a 
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sleep disorders specialist based on clinical history and overnight video-PSG recording using 
the criteria of the International Classification of Sleep Disorders, Second Edition (19). Forty-
four of iRBD patients were free of psychiatric medication at the time of the PSG, but 26 were 
taking antidepressant or anxiolytic medication. However, for all patients (except one) on 
medication at the moment of the PSG, RBD symptoms onset predated the taking of 
psychiatric medication.  Fifty-five patients met the inclusion criteria (42 men; mean age 64.80 
± 9.53 years; age range from 36 to 81 years; mean RBD duration from symptoms onset 10.38 
± 8.47 years). Twelve patients were excluded for dementia, one for PD, one for drug-induced 
RBD and one for age over 90 years. Sixty-three control subjects met the inclusion criteria (47 
men; mean age 63.79 ± 9.45 years; age range from 42 to 86 years). One control subjects were 
excluded for age over 90 years old. 
 
For comparison purposes, the iRBD group was later divided into subgroups according to 
gender, age of RBD symptoms onset (early-onset = <50 years/late-onset = >50 years; 16), use 
of psychiatric medication (with/without), and past psychiatric diagnoses (with/without). We 
considered “with” psychiatric medication subjects taking a mood stabilizer, antidepressant, or 
anxiolytic medication at the time of the study. Forty percent (22/55) of iRBD patients were 
taking psychiatric medication. Fifteen were taking antidepressants, nine were taking 
anxiolytics, and three were taking a mood stabilizer. Two control subjects were taking an 
anxiolytic. An additional 13 iRBD patients were taking clonazepam solely to treat RBD 
symptoms. They were included in the “without” psychiatric medication group when assessed 
for depressive symptoms, due to the low dose, time of administration (before bedtime) and 
clonazepam is not an antidepressant medication. However, these patients were included in the 
“with” psychiatric medication group when assessed for anxiety symptoms. Past psychiatric 
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diagnoses was determined by a structured interview in controls and by reviewing the medical 
records in iRBD, the same method used in previous studies (2,5,16). At their visit at the sleep 
clinic for the evaluation or the follow-up of their RBD condition, each patient was evaluated 
by a psychiatrist who conducted a structured clinical interview.  
 
Assessment of mood symptoms 
Mood symptoms were assessed with the French version of the Beck Depression Inventory – 
Second Edition (BDI-II; 20) and the Beck Anxiety Inventory (BAI; 21). A research assistant 
reviewed the validity of the answers after the administration of the questionnaires. The BDI-II 
is a self-administered depression screening inventory composed of 21 items rated on a 4-point 
Likert scale ranging from 0 to 3, higher scores indicating higher levels of depressive 
symptoms. According to the interpretation guidelines (20), the score in BDI-II ranges from 0 
to 13 in patients with minimal depression, 14 to 19 with mild, 20 to 28 with moderate and 29 
to 63 with severe depression. A score >13 on the BDI-II was used to determine the presence 
of clinically significant depressive symptoms (20). In order to exclude confounding factors 
that could overestimate depressive symptoms in some patients, we also applied the BDI for 
Primary Care (BDI-PC; 22). The BDI-PC includes seven items from the original BDI-II 
(sadness, pessimism, past failure, loss of pleasure, self dislike, self criticism, and suicidal 
ideation), specifically chosen for better association with a depression diagnosis. A score >3 on 
the BDI-PC was used to determine the presence of clinically significant depressive symptoms 
(22). 
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Of the 55 iRBD patients who completed the BDI-II, 43 also completed the BAI (33 men; 
mean age, 64.41 ± 8.75 years; age range from 36 to 80 years; mean RBD duration from 
symptoms onset 8.88 ± 7.46 years). Scores were compared to those of 50 control subjects (34 
men; mean age, 66.34 ± 8.67 years; age range from 45 to 86 years). The BAI is a 21-item self-
report questionnaire rated on a 4-point Likert scale ranging from 0 to 3, higher scores 
indicating higher levels of anxiety symptoms. According to the guidelines (21), a BAI score 
ranging from 0 to 7 reflects a minimal level of anxiety, 8 to 15 indicates mild, 16 to 25 
indicates moderate, and 26 to 63 indicates severe anxiety. A score >7 on the BAI indicates the 
presence of clinically significant anxiety symptoms (21). 
 
Statistical analysis  
Normally distributed continuous data were compared between groups using bilateral student 
t-tests for independent samples. For variables that were not distributed normally, between-
group differences were assessed using the nonparametric Mann-Whitney U test. Chi-square 
test (Yates corrected) was used to compare the proportion of participants. Correlations 
between measured values were determined by Pearson correlation analysis for normally 
distributed data or Spearman’s test for non-normally distributed data. Results are expressed as 
means ± standard deviation and a statistical significance was considered at p < 0.05. 
 
RESULTS 
No between-group difference was found for age. The proportion of participants with past 
psychiatric diagnoses was higher (χ2 test = 7.25; 1 degree of freedom [df]; p = 0.007) in the 
iRBD group (17/55 or 31%; affective disorder = 6, anxiety disorder = 4 and subjects with 
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more than one psychiatric diagnosis = 7) than the control group (6/63 or 9.5%; affective 
disorder = 4, subjects with more than one psychiatric diagnosis = 2). 
 
Depressive symptoms 
iRBD patients scored significantly higher on the BDI-II than controls (9.63 ± 6.61 vs. 4.32 ± 
4.58; p < 0.001) (Figure 1). Moreover, iRBD patients scored significantly higher than 
controls on the BDI-PC (2.20 ± 2.29 vs. 0.98 ± 1.53; p = 0.001). The proportion of subjects 
with clinically significant depressive symptoms was higher in the iRBD than control group 
(12/55 or 22% vs. 4/63 or 6%, X2 = 4.75; 1 df; p = 0.03). Seven subjects in the iRBD group 
(11%) had mild depressive symptoms, four (7%) had moderate depressive symptoms, and one 
had severe depressive symptoms. All subjects in the control group with clinically significant 
depressive symptoms were classified as mildly depressive. Moreover, the proportion of iRBD 
patients with clinically significant depressive symptoms remains similar using the BDI-PC 
(11/55 or 20%), but only a trend was found compared to control subjects (6/63 or 10%; X2 = 
2.42; 1 df; p = 0.18).  
____________________________ 
Insert Figure 1 approximately here 
____________________________ 
 
BDI-II scores were significantly higher for women than men, for patients taking psychiatric 
medication than those free of psychiatric medication, and for patients with past psychiatric 
diagnosis than those without past psychiatric diagnosis (Table 1). However, men with iRBD 
also scored higher than control men (8.26 ± 5.53 vs. 4.13 ± 4.59; p < 0.001) as well as women 
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with iRBD than control women (14.07 ± 8.00 vs. 4.88 ± 4.62; p = 0.001). Moreover, iRBD 
patients not taking psychiatric medication scored higher than similar controls (7.69 ± 5.22 vs. 
4.04 ± 4.38; p < 0.001) and iRBD patients without past psychiatric diagnosis scored higher 
than similar controls (8.18 ± 5.55 vs. 3.89 ± 4.17; p < 0.001).  
 
____________________________ 
Insert Table 1 approximately here 
____________________________ 
 
Anxiety symptoms 
iRBD patients scored significantly higher on the BAI than controls (8.37 ± 7.30 vs. 3.92 ± 
5.26; p < 0.001) (Figure 2). A higher proportion of iRBD patients had clinically significant 
anxiety symptoms than controls (21/43 or 49% vs. 9/50 or 18%, X2 = 8.70; 1 df; p = 0.003). In 
the iRBD group, 13 subjects (30%) had mild anxiety symptoms, seven (16%) had moderate 
anxiety symptoms, and one had severe anxiety symptoms (2%). In the control group, eight 
subjects (16%) had mild anxiety symptoms and one (2%) had moderate symptoms. 
 
iRBD patients taking psychiatric medication scored significantly higher on the BAI than those 
without psychiatric medication (Table 2). This is consistent with the higher proportion of 
subjects taking psychiatric medication who present with clinically significant anxiety 
symptoms. No significant difference was in iRBD patients not taking psychiatric medication 
compared to similar controls (3.33 ± 2.93 vs. 3.69 ± 5.15; p = 0.60). Moreover, iRBD patients 
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with past psychiatric diagnosis scored significantly higher on the BAI than those without past 
psychiatric diagnosis. Similar results were observed when participants with past psychiatric 
diagnosis were excluded in both groups (6.99 ± 7.24 vs. 3.31 ± 3.87; p = 0.01). 
____________________________ 
Insert Figure 2 approximately here 
____________________________ 
____________________________ 
Insert Table 2 approximately here 
____________________________ 
 
In iRBD, a positive correlation was found between BDI-II and BAI scores (r=0.621; p < 
0.001). No correlation was found between BDI-II or BAI scores and age or RBD duration.  
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DISCUSSION 
Our results show that patients with iRBD exhibit more severe depressive and anxiety 
symptoms than control subjects. Moreover, a higher proportion of iRBD patients than 
controls reported clinically significant depressive or anxiety symptoms. Similar to 
another study (16), we found that more iRBD patients than controls had past psychiatric 
diagnosis, mainly involving affective and anxiety disorders. In fact, 31% of our iRBD 
patients had a lifetime history of psychiatric disorders which is similar to the 
Rochester’s series (26%; 2) or the Hong Kong Chinese’s cohort (33%; 5). A positive 
correlation was found between BDI-II and BAI scores in the iRBD group. Thus, the 
results of the present study indicate that routine examination of patients with iRBD 
should include an assessment of psychiatric symptoms to prevent their appearance and 
offer therapeutic alternatives.  
We found that 22% of individuals in the iRBD group had clinically significant 
depressive symptoms, compared to 6% of controls. A limitation of our study might be 
that our control group is not representative of the general population. However, in 
Quebec’s elderly population, the prevalence of depression has been estimated at 6.8% 
(4.6% in men and 8.3% in women; 23), which is similar to the prevalence reported in 
other countries (24). Our results also show that 49% of iRBD subjects and 18% of 
controls had clinically significant anxiety symptoms. The prevalence of anxiety 
disorders in Quebec’s elderly population has been estimated at 5.6% (3.6% in men and 
6.9% in women; 23), with an even higher prevalence of anxiety symptoms (>15% in the 
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community samples; 25). This is similar to the prevalence observed in other countries 
(25). Therefore, our estimated prevalence of depression and anxiety is higher in iRBD 
subjects and approximately similar in controls to the estimates for Quebec’s general 
population or for other countries. However, differences in the proportion of men to 
women limit direct comparison. 
 
Our study identifies female gender as a risk factor for more severe depressive 
symptoms in iRBD. This is similar to the general population, where women have a 
higher prevalence of depression than men (23,24,25). However, our iRBD and control 
groups were matched for gender, and the severity of depressive symptoms was higher in 
males with iRBD compared to male controls. Other risk factors for more severe 
depressive or anxiety symptoms identified in our study are the use of psychiatric 
medication and the presence of past psychiatric diagnosis. This is consistent with the 
results reported in the literature (24). 
We found that iRBD patients taking psychiatric medication, mainly antidepressants or 
anxiolytics, reported more severe depressive or anxiety symptoms. Different 
explanations may be proposed for this. First, the psychiatric medication may actually 
lower inventory scores that would be even higher without psychiatric medication. 
Second, the efficacy of the psychiatric medication may be questioned. Antidepressants 
such as selective serotonin reuptake inhibitors and tricyclic are largely used in PD. 
However, their efficacy in treating depression in PD is in dispute (27-29). Moreover, 
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the efficacy of pharmacologic treatment of anxiety in PD has not been well 
demonstrated (30). Given the association between iRBD and the development of PD, 
which suggests some similarities in their pathophysiology, it is also possible that iRBD 
patients treated for depression or anxiety may not benefit from their medications. 
However, further studies are needed to better determine the efficacy of psychiatric 
medications in iRBD. 
 
In the present study, we used two widely employed scales to assess the severity of 
depressive and anxiety symptoms in iRBD. The BDI-II is a modified version of the 
original BDI, designed to better correspond to the DSM-IV criteria for major depression 
(20). The BDI-II appears to have strong validity as a screening measure for depression 
in older adults in the general population (31). Although the BDI-II does not have an 
equal number of items for each criterion of the DSM-IV, it covers all the cognitive and 
somatic-affective dimensions of major depression. Although the validity of the BDI-II 
to assess depressive symptoms in iRBD has never been established, it has been 
demonstrated valid for screening and measuring depressive symptom severity in PD 
(32). 
 
BAI measures the severity of somatic, affective, and cognitive symptoms associated 
with anxiety (21). It has good validity, especially in assessing panic attack symptoms, 
as it covers 10 of the 13 criteria listed in the DSM-IV. It is probably more suited to 
screening panic attacks than other anxiety dimensions such as generalized anxiety 
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disorder (33). This makes it a reliable tool for assessing anxiety in PD, panic disorder 
being one of the most frequent dimensions of anxiety in this neurodegenerative disease 
(34). Although the validity of the BAI for assessing anxiety symptoms in iRBD has 
never been established, its use has been suggested to measure anxiety in PD (33). 
 
Two hypotheses may explain the high frequency of depressive and anxiety symptoms in 
iRBD. First, iRBD and depression/anxiety may share common neuronal and 
neurotransmitter deficiencies. The physiopathology of RBD involves brain regions that 
regulate REM sleep (35), including the noradrenergic locus coeruleus/subcoeruleus and 
the serotoninergic raphe systems. These structures have connections with the limbic 
system, basal ganglia, and hypothalamus, areas involved in the regulation of emotions 
that were also shown to play a role in depression and anxiety (36). Moreover, RBD 
represents an early stage in the development of synucleinopathies such as PD or DLB. 
A high prevalence of depression and anxiety was previously reported in these 
conditions (13-15). Some studies also reported that depressive and anxiety symptoms 
often develop before the onset of parkinsonism in PD and DLB (37-39). Follow-up 
studies comparing the risk of developing a neurodegenerative disease in iRBD 
according to their psychiatric status are needed to better understand this possible link. 
 
The second hypothesis is that the presence of comorbidities in iRBD directly results in 
depression and anxiety. Indeed, iRBD patients often present olfactive loss (12), 
dysautonomia (erectile dysfunction, constipation, urinary symptoms; 12), mild cognitive 
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impairment (11,40), or subtle motor impairment (12), that might reduce their quality of 
life and increase the risk of developing depressive or anxiety symptoms. Sleep 
disruption and fear of hurting themselves or the bed partner, which are very frequent in 
iRBD (2,3), and the stress of a higher risk of developing a neurodegenerative disease in 
the future may also be psychological burdens that could trigger and maintain a mood 
disorder. However, the higher score for the iRBD group and the unchanged proportion 
of iRBD patients with clinically significant depressive symptoms on the BDI-PC, which 
was developed to minimize the contribution of confounding factors, suggests that 
comorbidities might not be the primary causes of psychiatric symptoms in iRBD. 
Further studies are needed to better understand the pathophysiology of psychiatric 
symptoms in iRBD and the role of comorbidities. 
 
 
 
 
 
 
 
 
 
 
39 
 
 
 
REFERENCES 
 
1. Schenck CH, Mahowald MW: REM sleep behavior disorder: clinical,   
developmental, and neuroscience perspectives 16 years after its formal 
identification in SLEEP. Sleep  2002;25:120-138 
 
2. Olson EJ, Boeve BF, Silber MH: Rapid eye movement sleep behavior disorder: 
 demographic, clinical and laboratory findings in 93 cases. Brain 
2000;123(Pt2):331-339 
 
3. Schenck CH, Hurwitz TD, Mahowald MW: REM sleep behaviour disorder: an 
update  on a series of 96 patients and a review of the world literature. J Sleep 
Res1993;2(4):224-231 
 
4. Ohayon MM, Caulet M, Priest RG: Violent behavior during sleep. J Clin 
Psychiatry 1997;58(8):369-376 
 
5. Wing YK, Lam SP, Li SX, et al: REM sleep behaviour disorder in Hong Kong 
 Chinese: clinical outcome and gender comparison. J Neurol Neurosurg 
 Psychiatry 2008;799(12):1415-1416 
 
6. Gagnon JF, Postuma RB, Montplaisir J: Update on the pharmacology of REM 
sleep  behavior disorder. Neurology 2006;67(5):742-747 
40 
 
 
 
 
7. Postuma RB, Gagnon JF, Vendette M, et al: Quantifying the risk of 
neurodegenerative  disease in idiopathic REM sleep behavior disorder. 
Neurology 2009;72(15):1296-130 
 
8. Iranzo A, Molinuevo JL, Santamaria J, et al: Rapid-eye-movement sleep 
behaviour  disorder as an early marker for a neurodegenerative disorder: a 
descriptive study. Lancet Neurol 2006;5(7):572-577 
 
9. Schenck CH, Bundlie SR, Mahowald MW: Delayed emergence of a 
parkinsonian  disorder in 38% of 29 older men initially diagnosed with 
idiopathic rapid eye  movement sleep behaviour disorder. Neurology 
1996;46(2):388-393 
 
10. Montplaisir J, Gagnon JF, Fantini ML, et al: Polysomnographic diagnosis of 
idiopathic REM sleep behavior disorder. Mov Disord 2010 Oct 15;25(13):2044-
2051 
 
11. Gagnon JF, Vendette M, Postuma RB, et al: Mild cognitive impairment in rapid 
eye  movement sleep behavior disorder and Parkinson's disease. Ann Neurol 
2009;66(1):39-47 
 
41 
 
 
 
12. Postuma RB, Gagnon JF, Vendette M. Monplaisir JY: Markers of 
neurodegeneration  in idiopathic rapid eye movement sleep behaviour disorder 
and Parkinson's disease.  Brain 2009;132(Pt 12):3298-3307 
 
13. Aarsland D, Bronnick K, Ehrt U, et al: Neuropsychiatric symptoms in patients 
with  Parkinson's disease and dementia: frequency, profile and associated care 
giver stress. J  Neurol Neurosurg Psychiatry 2007;78(1):36-42 
 
14. Benrud-Larson LM, Sandroni P, Schrag A, Low PA: Depressive symptoms and 
life  satisfaction in patients with multiple system atrophy. Mov Disord 
2005;20(8):951-957 
 
15. Dodel R, Csoti I, Ebersbach G, et al: Lewy body dementia and Parkinson's 
disease  with dementia. J Neurol 2008;255(Suppl 5):39-47 
 
16. Teman PT, Tippmann-Peikert M, Silber MH, et al: Idiopathic rapid-eye-
movement  sleep disorder: associations with antidepressants, psychiatric 
diagnoses, and other  factors, in relation to age of onset. Sleep Med 
2009;10(1):60-65 
 
42 
 
 
 
17. American Psychiatric Association: DSM-IV-TR: Diagnostic and statistical 
manual of  mental disorders. 4th ed. Text revision. Washington, DC 2000. 
American Psychiatric Association 
 
18. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of 
idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51(6):745-
752 
 
19. American Academy of Sleep Medicine: Task Force Chair; Hauri PJ, Chairman. 
The  international classification of sleep disorders: diagnostic and coding 
manual. 2nd ed. Westchester IL 2005. American Academy of Sleep Medicine 
 
20. Beck AT, Steer RA, Brown G: Beck Depression Inventory (2nd edition). San 
Antonio, TX 1996. The Psychological Corporation 
 
21. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical 
anxiety: psychometric properties. J Consult Clin Psychol 1988;56(6):893-7 
 
22. Beck AT, Guth D, Steer RA, et al: Screening for major depression disorders in 
 medical inpatients with the Beck Depression Inventory for Primary Care. Behav 
Res  Ther 1997;35:785-791 
 
43 
 
 
 
23. Préville M, Boyer R, Grenier S, et al: The epidemiology of psychiatric disorders 
in Quebec's older adult population. Can J Psychiatry 2008;53(12):822-832 
 
24. Djernes J:. Prevalence and predictors of depression in populations of elderly: a 
 review. Acta Psychiatr Scand 2006;113(5):372-387 
 
25. Bryant C, Jackson H, Ames D: The prevalence of anxiety in older adults: 
 methodological issues and a review of the literature. J Affect Disord 
2008;109(3): 233-250 
 
26. Kuehner C: Gender differences in unipolar depression: an update of 
epidemiological findings and possible explanations. Acta Psychiatr Scand 
2003;108:163-174 
 
27. Shabnam GN, Th C, Kho, H R, Ce C: Therapies for depression in Parkinson's 
disease. Cochrane Database Syst Rev 2003;CD003465 
 
28. Miyasaki JM, Shannon K, Voon V,  et al: Practice Parameter: evaluation and 
treatment of depression, psychosis, and dementia in Parkinson disease (an 
evidence-based review): report of the Quality Standards Subcommittee of the 
American Academy of  Neurology. Neurology 2006;66(7):996-1002 
 
44 
 
 
 
29. Weintraub D, Morales KH, Moberg PJ, et al: Antidepressant studies in 
Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20(9):1161-
1169 
 
30. Ferreri F, Agbokou C, Gauthier S: Recognition and management of 
neuropsychiatric complications in Parkinson's disease. CMAJ 
2006;175(12):1545-1552 
 
31. Segal DL, Coolidge FL, Cahill BS, et al: Psychometric properties of the Beck 
 Depression Inventory II (BDI-II) among community-dwelling older adults. 
Behav  Modif 2008;32(1):3-20 
 
32. Schrag A, Barone P, Brown RG, et al: Depression rating scales in Parkinson's 
disease: critique and recommendations. Mov Disord 2007;22(8):1077-1092 
 
33. Leentjens AF, Dujardin K, Marsh L,  et al: Anxiety rating scales in Parkinson's 
 disease: critique and recommendations. Mov Disord 2008;23(14):2015-2025 
 
34. Richard IH:. Anxiety disorders in Parkinson's disease. Adv Neurol 2005;96:42-
55 
 
45 
 
 
 
35. Boeve BF, Silber MH, Saper CB, et al: Pathophysiology of REM sleep 
behaviour disorder and relevance to neurodegenerative disease. Brain 
2007;130(Pt 11):2770-2788 
 
36. Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 
 2008;455(7215):894-902 
 
37. Weisskopf MG, Chen H, Schwarzschild MA, et al: Prospective study of phobic 
 anxiety and risk of Parkinson's disease. Mov Disord 2003;18(6):646-651 
 
38. Remy P, Doder M, Lees A, et al: Depression in Parkinson's disease: loss of 
dopamine and noradrenaline innervation in the limbic system. Brain 
2005;128(Pt 6):1314-1322 
 
39. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR: 
Higher incidence of depression preceding the onset of Parkinson's disease: a 
register study. Mov Disord 2003;18(4):414-418 
 
40. Ferini-Strambi L, Di Gioia MR, Castronovo V, et al: Neuropsychological 
assessment  in idiopathic REM sleep behavior disorder (RBD): does the 
idiopathic form of RBD  really exist? Neurology 2004;62(1):41-45 
 
46 
 
 
 
FIGURE LEGENDS 
Figure 1  
Beck Depression Inventory Second Edition (BDI-II) scores distribution. Dotted 
horizontal bars indicate mean group values. Full horizontal bar indicates the cut-off 
value (score >13) for clinically significant depressive symptoms. iRBD = idiopathic 
REM sleep behavior disorder. 
 
Figure 2  
Beck Anxiety Inventory (BAI) scores distribution. Dotted horizontal bars indicate mean 
group values. Full horizontal bar indicates the cut-off value (score >7) for clinically 
significant anxiety symptoms. iRBD = idiopathic REM sleep behavior disorder. 
 
 
 
 
 
 
 
 
 
 
 
47 
 
 
 
Table 1 – Between-subgroups comparisons for the Beck Depression Inventory Second 
Edition 
RBD = REM sleep behavior disorder; BDI-II = Beck Depression Inventory Second 
Edition; ns = not significant. The data was analysed using Mann-Whitney test, except 
for the age variables, where Student t-test was employed. 
 
 
 
 
 
 
Women (N=13) Men (N=42) p 
Age 67.4 ± 6.6 64.0 ± 10.2 ns 
RBD duration 9.7 ± 8.4 10.6 ± 8.6 ns 
BDI-II 
   >13 
14.1 ± 8.0 
5 
8.3 ± 5.5 
7 
0.02 
ns 
 
Early onset (N=16) Late onset (N=39) p 
Age 57.2  ± 12.1 68.0 ± 6.1 ---- 
Gender (w/m) 2/14 11/28 ns 
BDI-II 
   >13 
8.9 ± 5.6 
4 
9.9 ± 7.2 
8 
ns 
ns 
 With medication (N=22) Without medication (N=33) p 
Age 65.9 ± 5.9 64.1 ± 11.4 ns 
Gender (w/m) 7/15 6/27 ns 
RBD duration 9.7 ± 9.2 10.8 ± 8.1 ns 
BDI-II 
   >13 
12.5 ± 7.2 
6 
7.7 ± 5.5 
6 
0.01 
ns 
 
With past psychiatric 
diagnosis (N=17) 
Without past psychiatric 
diagnosis (N=38) 
p 
Age 65.0 ± 9.8 64.3 ± 9.1 ns 
Gender (w/m) 6/11 7/31 ns 
RBD duration 9.9 ± 9.3 10.6 ± 8.2 ns 
BDI-II 
   >13 
12.9 ± 7.8 
6 
8.2 ± 5.5 
6 
0.04 
ns 
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Table 2 – Between-subgroups comparisons for the Beck Anxiety Inventory 
RBD = REM sleep behavior disorder; BDI-II = Beck Depression Inventory Second 
Edition; ns = not significant. The data was analysed using Mann-Whitney test, except 
for the age variables, where Student t-test was employed. 
 
 Women (N=10) Men (N=33) p 
Age 66.2 ± 6.9 63.9 ± 9.3 ns 
RBD duration 8.4 ± 8.7 9.0 ± 7.2 ns 
BAI 
   >7 
11.00 ± 7.33 
7 
7.57 ± 7.20 
14 
ns 
ns 
 Early onset (N=11) Late onset (N=32) p 
Age 57.3 ± 11.3 66.9 ± 6.2 --- 
Gender (w/m) 2/9 8/24 ns 
BAI 
   >7 
8.3 ± 6.7 
6 
8.4 ± 7.6 
15 
ns 
ns 
 With medication (N=31) 
Without medication 
(N=12) 
p 
Age 65.1 ± 7.4 62.6 ± 11.7 ns 
Gender (w/m) 10/21 0/12 ns 
RBD duration 10.1 ± 8.4 5.7 ± 2.4 ns 
BAI 
   >7 
10.3 ± 7.6 
19 
3.3 ± 3.0 
2 
0.001 
0.02 
 
With past psychiatric 
diagnosis (N=15) 
Without past psychiatric 
diagnosis (N=28) 
p 
Age 63.9 ± 9.4 64.7 ± 8.5 ns 
Gender (w/m) 6/9 4/24 ns 
RBD duration 8.9 ± 8.5 8.9 ± 7.0 ns 
BAI 
   >7 
11.1 ± 6.8 
10 
7.0 ± 7.2 
11 
0.03 
ns 
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Figure 1. BDI-II scores distribution. Dotted horizontal bars indicate mean group values. 
Full horizontal bar indicates the cut-off value (score >13) for clinically significant 
depressive symptoms. iRBD = idiopathic REM sleep behavior disorder. 
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Figure 2. BAI scores distribution. Dotted horizontal bars indicate mean group values. 
Full horizontal bar indicates the cut-off value (score >7) for clinically significant 
anxiety symptoms. iRBD = idiopathic REM sleep behavior disorder. 
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5.2 Additional results 
This section includes results that have not been included in the initial paper, but were 
deemed useful afterwards in order to reinforce our results.  
As can be noticed in the Table 1 (chapter 8.2 in Addendum), the results illustrate that 
our patients’ group have the characteristics of RBD signs according to the criteria 
described in this thesis: percentage of tonic activity 39.4±22.2 and of phasic activity 
32.0±12. In the same time, parameters such as the efficiency of total sleep and REM 
sleep (mean time 378.2±59.4 minutes), percentage of time spent in stage 1 (11.6±6.7), 
stage 2 (62.8±7.0), SWS (7.3±6.8) and REM sleep (18.2±6.6) show a normal group for 
the age and sex, supporting the affirmation that RBD patients preserve the architecture 
of their sleep. 
The patients in our study have not passed REM sleep behavior disorder severity scale 
(RBDSS), a scale designed to assess the severity of RBD in a clinical setting. However, 
we have considered the percentage of tonus and phasic activity in each patient as a 
measure of the severity of the disorder. As shown in the table 2 (chapter 8.2), we have 
not found any statistically significant correlations between the chosen variables. We 
have found what seems to be a trend in two correlations (BDI score with RBD duration, 
p=0.07, and BAI score with percentage of phasic activity, p=0.07), but a larger group of 
patients and further analysis are probably needed in order to confirm this finding. 
Some of our RBD patients were treated with clonazepam for their disorder. As 
clonazepam is a barbiturate with a presumed anxiolytic effect, we have tested an 
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eventual anxyolitic effect of the drug in our patients. The results are presented in Table 
3 in the ADDENDUM. The groups were defined as follows: With Clonazepam – 
patients that were taking ONLY clonazepam, excluding any other psychiatric 
medication (namely other benzodiazepines and antidepressants) and Without 
clonazepam – patients free of ANY psychiatric medication, including clonazepam. We 
have found a significant difference between the scores of the two groups, namely 
patients taking clonazepam only had significantly higher scores than those free of 
medication. As hypothesized in the discussion of the article included into the thesis, 
clonazepam taken at the weak doses used for the treatment of iRBD probably cannot 
account as treatment for anxiety symptoms. Moreover, clonazepam may lower BAI 
scores that otherwise could be even higher in the absence of treatment.   
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6. DISCUSSIONS AND PERSPECTIVES 
6.1 Psychiatric symptoms in iRBD 
Our study shows that patients with iRBD exhibit more severe depressive and anxiety 
symptoms than sex and age matched controls. Moreover, a higher proportion of iRBD 
patients than controls reported past history of psychiatric diagnoses as well as clinically 
significant depressive or anxiety symptoms. A positive correlation was found between 
BDI-II and BAI scores in the iRBD group. This is not a surprising result, since earlier 
reports show that depressive and anxiety symptoms are often comorbid (Olfson et al, 
2011). Thus, the results indicate that routine examination of patients with iRBD should 
include an assessment of psychiatric symptoms to prevent their occurrence and offer 
therapeutic alternatives. 
We have found that 6% of control subjects recruited in our study show significant 
depressive symptoms. In Quebec’s elderly population, the prevalence of depression has 
been estimated at 6.8% (4.6% in men and 8.3% in women) (Preville et al., 2008). This 
estimate includes both major depressive disorder (MDD) and dysthymia (i.e., minor 
depressive disorder) for both genders. However, MDD prevalence was 1.1%, and the 
prevalence of dysthymia, a milder depressive disorder that does not meet the criteria for 
MDD, was 5.7%, similar to our findings (Preville et al., 2008). Our results also show 
that 49% of iRBD subjects and 18% of controls had clinically significant anxiety 
symptoms. The prevalence of anxiety disorders in Quebec’s elderly population has been 
estimated at 5.6% (3.6% in men and 6.9% in women), with an even higher prevalence 
of anxiety symptoms (>15% in the community samples). A prevalence of 15.3%, 
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including the entire spectrum of anxiety disorders, was also found in a >60-year-old 
subgroup of a study population (Kessler et al., 2005). Therefore, our estimated 
prevalence of depression and anxiety is higher in iRBD patients and approximately 
similar in controls compared to the estimates for the general population in Quebec and 
in other countries. However, differences in the proportion of men to women limit direct 
comparison. 
 
Similar to the study by Teman (2009), we found that more iRBD patients than controls 
had a past psychiatric diagnosis, mainly involving affective and anxiety disorders. In 
fact, 31% of our iRBD patients had a lifetime history of psychiatric disorders, which is 
similar to Rochester’s series (26%) (affective disorders: 10.7%, substance abuse: 9.7%, 
anxiety disorders: 4.3%, personality disorders: 3.2%) and the results on a cohort of 
Hong Kong Chinese patients (33%), but higher than the percentage reported in the 
Minneapolis series (9%) (Schenck, 1993). All three cohorts are similar with respect to 
number of participants, age, and gender distribution. In our study, gender distribution 
was similar to that in the other cohorts, with 77% male predominance (42 men), 
although our sample was smaller (55 patients in the iRBD group). None of the three 
above-mentioned studies provides a thorough description of the method used to 
determine psychiatric status, which was probably based on patient history alone, thus 
excluding potential undiagnosed conditions. Wing alone mentions in his Hong Kong 
study that patients’ medical and psychiatric histories were based on a case note review 
and computerized records. In our study, past psychiatric diagnosis was determined by a 
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structured interview with controls and by reviewing the medical records of the iRBD 
group. Furthermore, at their visit to the sleep clinic for the evaluation and follow-up of 
their RBD condition, each patient underwent a structured clinical interview by a 
psychiatrist. 
 
Schenck et al (1996) specifically searched for psychiatric disorders and/or their 
treatment that were “causally associated” with the RBD onset, and did not evaluate the 
entire psychiatric spectrum of the patients, regardless of an alleged link to RBD status. 
Moreover, 7 of the 9 identified psychiatric disorders had a clear organic origin (alcohol 
cessation, amphetamine use, cocaine abuse, fluoxetine treatment for obsessive-
compulsive disorder), which may be termed drug-induced RBD.  
 
6.2. Risk factors for psychiatric symptoms in iRBD 
Our study identifies female gender as a risk factor for more severe depressive 
symptoms in iRBD. The gender difference in depression is one of the most consistent 
epidemiological findings in the research, holding true across cultures (Bebbington, 
1996; Nolen-Hoeksema, 1996; Preville et al., 2008; Kessler et al., 2005) Different 
responses to stressful stimuli as well as societal gender roles, hormonal differences, 
psychosocial factors, and artifactual aspects of help-seeking have all been cited to 
explain these differences. However, our iRBD and control groups were matched for 
gender, and the severity of depressive symptoms was higher in males with iRBD than in 
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male controls, suggesting that the gender difference alone did not account for the 
depressive symptoms. Other risk factors for the more severe depressive or anxiety 
symptoms identified in our study are the use of psychiatric medication, use of 
clonazepam alone (Table 3) and the presence of past psychiatric diagnosis. This is 
consistent with other results reported in the literature (Djernes et al., 2006). 
Severity of REM symptoms in our patients, measured as percentage of tonic and phasic 
activity, is not a risk factor in developing more severe depression or anxiety symptoms 
since we found no correlation between the variables, as shown in Table 2 (section 5.2, 
page 52).  
 
6.3 Psychiatric symptoms inventories 
In the present study, we assessed the severity of depressive and anxiety symptoms in 
iRBD with two widely used scales: the BAI-II (Beck et al., 1996) and the BAI (Beck et 
al., 1988). The BAI-II is a modified version of the original BDI, designed to better 
correspond to the DSM-IV criteria for major depression. The BDI-II appears to have 
strong validity as a screening measure for depression in older adults in the general 
population. Although the BDI-II does not include an equal number of items for each 
criterion of the DSM-IV, it covers all the cognitive and somatic-affective dimensions of 
major depression. Although the validity of the BDI-II to assess depressive symptoms in 
iRBD has never been established, it has been demonstrated valid for screening and 
measuring depressive symptom severity in PD. The BDI has been widely used in PD to 
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screen for depression, measure depression severity, and assess the response to 
pharmacological or surgical treatment (Schrag et al., 2007). The BDI-PC (Beck 
Depression Inventory – primary care) was designed to rule out confounding factors in a 
diagnosis of depression. It focuses on only 7 symptoms, which better match the DSM-
IV criteria for major depressive disorder: sadness and loss of pleasure, suicidal thoughts 
or wishes, pessimism, past failure, self dislike, and self criticalness (Beck et al., 1997).  
The BAI measures the severity of somatic, affective, and cognitive symptoms 
associated with anxiety (Beck et al., 1988). It has good validity, especially in assessing 
panic attack symptoms, as it covers 10 of the 13 criteria listed in the DSM-IV. It is 
probably more suited to screening panic attacks than other anxiety dimensions such as 
generalized anxiety disorder. This makes it a reliable tool for assessing anxiety in PD, 
panic disorder being one of the most frequent dimensions of anxiety in this 
neurodegenerative disease. Although the validity of the BAI for assessing anxiety 
symptoms in iRBD has never been established, its use has been suggested to measure 
anxiety in PD. 
The BDI and BAI were used to assess depressive and anxiety symptoms in the two 
weeks prior to the RBD diagnosis, and not at the time of the testing. 
 
6.4 Pathophysiology of cluster symptoms 
Two hypotheses may explain the high frequency of depressive and anxiety symptoms in 
iRBD. First, iRBD and depression and/or anxiety may share common neuronal and 
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neurotransmitter deficiencies. The physiopathology of RBD involves brain regions that 
regulate REM sleep, including the noradrenergic locus coeruleus/subcoeruleus and the 
serotoninergic raphe systems. These structures have connections with the limbic 
system, the basal ganglia, and the hypothalamus, which are involved in regulating the 
emotions that have been shown to play a role in depression and anxiety. Moreover, 
RBD represents an early stage in the development of synucleinopathies such as PD or 
DLB. Of the 93 patients included in a study by Postuma et al. (2009) 15 developed 
parkinsonism and 11 developed dementia. Of the patients with parkinsonism, 14 were 
diagnosed with idiopathic PD and 1 was diagnosed with MSA. Of the patients with 
dementia, 7 met the clinical criteria for LBD. The estimated 5-year risk of developing 
neurodegenerative disease (parkinsonism or dementia) was 17.7% (Postuma et al., 
2009). Similar studies have found that the risk of developing a synucleinopathy is 
between 38% at the initial report (Schenck et al., 1996) and 44% after a median follow-
up of 5 years (Iranzo et al., 2006).  
 
In recent years, a staging system for neurodegeneration in PD has been proposed. In the 
pattern proposed by Braak et al. (2003) neurodegeneration by alpha-synuclein 
deposition starts in the dorsal motor nucleus of the vagus and olfactory tracts (stage 1), 
spreads to other lower brainstem structures, including those that regulate sleep paralysis 
and mood (dorsal raphe, coeruleus/subcoeruleus complex) (stage 2), and only at stage 3 
begins to cause motor symptoms by affecting the substantia nigra pars compacta (SNpc) 
(Braak et al., 2006). Although the pathophysiology of depression in PD is complex and 
probably includes many structures, some of them have been identified in the brainstem, 
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including the dorsal motor nucleus of the vagus serotonin neurons of the dorsal raphae 
and the substantia nigra, and the catecholaminergic neurons of the locus coeruleus 
(Lieberman, 2006; Frisina, 2009; Walter, 2007). As described above, some of these 
structures are also involved in stage 2 of Braak’s scheme, along with RBD.  
 
A high prevalence of depression and anxiety has been previously reported in alpha-
synucleinopathies. There is evidence to suggest that depressive and anxiety symptoms 
often develop before the onset of parkinsonism in PD and DLB (Weisskopf et al., 2003; 
Remy et al., 2005; Leentjens et al., 2003). A national cohort retrospective study based 
on database diagnoses found a two- to four-fold increase in the risk of developing PD in 
patients with a history of depression (Ishihara, 2006).  
In addition, many case control studies have shown an increased risk of developing PD 
in patients with a history of depression (Ishihara et al., 2006). Furthermore, patients 
with depression may have abnormalities on SNpc sonnography that are similar to those 
observed in PD (Walter et al., 2007). Although depression in itself is unlikely to 
become a marker for early PD diagnosis, we might assume that the combination of two 
pre-motor symptoms (such as RBD and depression) with presumably the same 
neuropathologic basis could increase the specificity for a diagnosis of pre-motor PD. 
However, follow-up studies comparing the risk of developing a neurodegenerative 
disease in iRBD according to psychiatric status are needed to better understand this 
potential link. 
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The second hypothesis is that the presence of comorbidities in iRBD directly results in 
depression and anxiety. Indeed, iRBD patients often present olfactory loss, 
dysautonomia (erectile dysfunction, constipation, and urinary symptoms), mild 
cognitive impairment, or subtle motor impairment. These might reduce the quality of 
life and increase the risk of developing depressive or anxiety symptoms. Sleep 
disruption, frightening dreams, and fear of hurting themselves or their bed partner, 
which are frequent in iRBD, and the stress of a higher risk of developing a 
neurodegenerative disease in the future may also be psychological burdens that could 
trigger and maintain a mood disorder. However, the higher score for the iRBD group 
and the unchanged proportion of iRBD patients with clinically significant depressive 
symptoms on the BDI-PC, which was developed to minimize the contribution of 
confounding factors, suggests that comorbidities might not be the primary causes of 
psychiatric symptoms in iRBD. Further studies are needed to better understand the 
pathophysiology of psychiatric symptoms in iRBD and the role of comorbidities. 
 
As stated earlier in this paper, the sleep architecture in iRBD patients remains 
unchanged compared to healthy age and sex matched subjects (Montplaisir et al, 2010, 
Fantini et al, 2003). According to the additional data shown in section 5.2 (page 52), the 
patients included in our study also had normal polysomnographic characteristics for 
their age and sex (a mean total sleep time of 378.2±59.4 minutes, sleep efficiency of 
81.2±10.2, REM total sleep time of 69.9±29.9 and REM efficiency of 85.8±13.0). Thus, 
although in the present study we report depressive and anxiety symptoms comorbid 
with iRBD, there is no indication that our patients display changes in their sleep 
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architecture similar to changes seen in depressive or anxious patients such as reduced 
total sleep time, prolonged sleep latency, increased number of awakenings. In the same 
time, according to the results in the BDI-II and BAI scores, our patients do not reach in 
their psychiatric symptoms the intensity of major depressive disorder or anxiety 
disorders. 
 
Obstructive sleep apnea (OSA) is a prevalent condition in the general population, and 
leads to higher morbidity and mortality; however, relationships between OSA severity 
and sleep or psychological symptoms are unclear. A recent study (Macey et al, 2010) 
assessing the degree of comorbidities in relationship to the severity of OSA found 
abnormally high scores of depressive and anxiety symptoms of both BDI-II and BAI 
scales. However, these results did not correlate to the severity of the OSA (measured as 
apnea/hypopnea index). The authors conclude that the absence of correlation between 
symptoms and disease severity does not result from low levels of symptoms in their set 
of OSA patients and suggest that mechanisms other than the number and frequency of 
hypoxic events contribute to adverse health effects in this patient population. 
Depressive and anxiety symptoms associated with OSA have been shown to induce 
neural changes brain regions such as parietal, bilateral hypocampus and left 
ventrolateral temporal cortices (Cross et al, 2008; Kumar et al, 2009), similar regions to 
those found in SPECT studies to be involved in iRBD patients (Vendette et, 2011). A 
subsequent neuroimaging study comparing the regions involved in iRBD and in OSA 
patients would probably shed some light into the pathophysiology of depressive and 
anxiety symptoms as comorbidities in iRBD patients.  
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6.5 Limitations of the study 
The present study has some limitations. Our recruitment method for iRBD patients and 
controls probably excluded participants with severe depressive or anxiety symptoms, 
who might have been unable to complete the procedure. However, we have compared 
our results in the control group to a study done on the prevalence of depressive and 
anxiety symptoms in aged population of Quebec (Preville et al 2008) and we have had 
comparable results in the proportion of controls with clinically significant symptoms of 
depression and anxiety, which led us to believe that out control group was 
representative. Because our evaluation was limited to a clinical interview and the 
administration of inventories of psychiatric symptoms, we might have underestimated 
the frequency and severity of depressive and anxiety symptoms in the participants.  
 
6.6 Perspectives 
The results of the present study open new perspectives to more in-depth studies of the 
mechanisms of psychiatric disorders in iRBD. Future approaches to this issue could 
take at least four directions:  
1. Standardize the psychiatric evaluation according to DSM-IV criteria. 
2. Investigate a potential link between iRBD comorbidities (olfaction, cardiac 
dysregulation, mild cognitive impairment, etc) and psychiatric symptoms.  
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3. Assess the brain regions that are potentially involved in psychiatric disorders in iRBD 
using functional or structural imaging techniques. 
4. Compare depressive and anxiety symptoms in PD patients with and without RBD. 
5. Determine whether depressive and anxiety symptoms in iRBD are predictive for the 
development of PD or DLB. 
Although treatment options for depression and anxiety in PD are limited at this point, 
RBD patients that present the above-described psychiatric profile may benefit from 
therapeutic strategies. 
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8.2 Tables 
Table 1. Polysomnographic characteristics of the RBD subgroup of patients that have 
passed the psychiatric inventories at the same moment as the polysomnographic 
investigation, expressed as mean ± standard deviation (N=25).  
Sleep latency (min) 
 
24.1±21.9  
 
REM total (min) 
 
69.9±29.9 
 
Sleep duration (min) 
 
378.2±59.4 
 
REM efficiency (%) 
 
85.8±13.0 
 
Sleep efficiency (%) 
 
81.2±10.2 
 
REM (%) 
 
18.2±6.6 
 
Stage1 (%) 
 
11.6±6.7 
 
Atonia (%) 
 
65.9±35.2 
 
Stage2 (%) 
 
62.8±7.0 
 
Tonus (%) 
 
39.4±22.2 
 
SWS (%) 
 
7.3±6.8 
 
Phasic (%) 
 
32.0±12.8 
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Table 2. Correlations between BDI-II and BAI scores with the percentage of tonic and 
phasic activity, age and duration of RBD symptoms in the patients’ group respectively. 
The analysis was made using Pearson correlation in SPSS. 
CORRELATION 
%Tonic 
activity 
%Phasic activity Age RBD duration 
BDI-II score p=0.6 p=0.3 p=0.7 p=0.07 
BAI score p=0.2 p=0.07 p=0.2 p=0.7 
 
Table 3. Comparison of BAI scores between patients taking only clonazepam and 
patients free of psychiatric medication. Results are expressed as mean ± standard 
deviation. 
 With clonazepam 
(N=10) 
Without clonazepam 
(N=12) 
p 
BAI score 10±9.6 3±3.1 0.03 
 
 
 
 
 
 
 
 
